预约演示
更新于：2025-07-16
Pantoprazole Sodium Hydrate
泮托拉唑钠
更新于：2025-07-16
概要
基本信息
简介安托拉唑是一种小分子药物，被归类为质子泵抑制剂，这意味着它可以减少胃中产生的酸量。 Takeda Pharmaceutical Co., Ltd. 于 1994 年 1 月首次批准该药物。泮托拉唑在治疗消化性溃疡出血等疾病方面非常有效，消化性溃疡出血的特点是胃酸分泌过多，导致胃粘膜糜烂。当酸分泌会引起疼痛和出血时，它也可用于治疗禁食。一般来说，泮托拉唑耐受性良好且不良反应极小，使其成为酸相关疾病的常见治疗选择。 |
药物类型 小分子化药 |
别名 Anagastra、Controloc、Eupantol + [51] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H17F2N3NaO5S |
InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N |
CAS号164579-32-2 |
关联
271
项与 泮托拉唑钠 相关的临床试验NCT06706258
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial): A Prospective Randomized Controlled Trial
IRCT20241017063400N1
Evaluation of the effectiveness of proton pump inhibitors (intravenous pantoprazole) in controlling vomiting in patients with acute gastroenteritis compared to fluid therapy and NPO
IRCT20200623047902N7
Bioequivalence study of Pantoprazole 40 mg tablet manufactured by Sanamed company versus the originator brand in fed and fast condition in healthy volunteers
100 项与 泮托拉唑钠 相关的临床结果
登录后查看更多信息
100 项与 泮托拉唑钠 相关的转化医学
登录后查看更多信息
100 项与 泮托拉唑钠 相关的专利（医药）
登录后查看更多信息
4,787
项与 泮托拉唑钠 相关的文献（医药）2025-08-12NEUROLOGY
Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease
Article
作者: Romanowska, Julia ; Scherzer, Clemens R. ; Bjornevik, Kjetil ; Cortese, Marianna ; Tuominen, Julia A. ; Igland, Jannicke ; Flores-Torres, Mario H. ; Riise, Trond
BACKGROUND AND OBJECTIVES:
There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course.
METHODS:
This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders.
RESULTS:
The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid).
DISCUSSION:
Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
2025-08-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Static and in-situ synchrotron X-ray microtomography analysis of pharmaceutical tablets
Article
作者: Küstner, Bernd ; Seim, Christian ; Westenberger, Peter ; Mattern, Enni ; Müller, Lena ; Doucet, Jean ; Hesse, Bernhard ; Schweitzer, Luiz ; Gerber, Javier ; Suuronen, Jussi-Petteri ; Weitkamp, Timm ; Bortel, Emely
Pharmaceutical solid dosage forms are designed to control drug release timing and location in the body, ranging from immediate-release to delayed-release formulations such as enteric-coated tablets. Ensuring content uniformity, consistent dissolution, and intact excipients is vital for their efficacy and safety. Manufacturing flaws - like defective coatings, cracks, or porosity - can compromise performance, making precise quality control essential. X-ray computed microtomography (µCT) enables non-destructive assessment of internal morphology, coating thickness, porosity, active ingredient distribution, and density. However, conventional laboratory µCT systems may lack the resolution, sensitivity, or speed required for advanced dynamic structural analysis. Synchrotron radiation-based µCT (SR-µCT) addresses these limitations, offering significant improvements in spatial resolution and temporal performance. This paper highlights the capabilities of SR-µCT for (i) high-throughput structural analysis and (ii) time-resolved monitoring of the dissolution of solid dosage forms. A commercially available pantoprazole tablet serves as a case study to demonstrate the tradeoff between resolution and field-of-view. Structural analysis of this pantoprazole tablet includes porosity and coating thickness quantification, as well as detection of morphological defects at different voxel sizes. Additionally, a newly developed flow-through chamber which allows liquid from a 100 ml reservoir to circulate and renew during measurements is presented for dynamic disintegration studies under sink conditions. Fast dynamic time-resolved SR-µCT analysis shows the disintegration speed of multicomponent placebo formulation compacted tablets at rapid µCT tomogram recording times of 5 s, while (high-resolution) time-resolved SR-µCT captures swelling in sustained-release formulations (Beloc Zok), API (size) distribution as well as API shape distribution.
2025-08-01MOLECULAR DIVERSITY
Leveraging machine learning to predict drug permeation: impact of menthol and limonene as enhancers
Article
作者: Raju, Baddipadige ; Kumar, Manoj ; Kaur, Jasveer ; Yadav, Manisha ; Sapra, Bharti ; Silakari, Om ; Narendra, Gera
The present study aimed to develop robust machine learning (ML) models to predict the skin permeability of poorly water-soluble drugs in the presence of menthol and limonene as penetration enhancers (PEs). The ML models were also applied in virtual screening (VS) to identify hydrophobic drugs that exhibited better skin permeability in the presence of permeation enhancers i.e. menthol and limonene. The drugs identified through ML-based VS underwent experimental validation using in vitro skin penetration studies. The developed model predicted 80% probability of permeability enhancement for Sumatriptan Succinate (SS), Voriconazole (VCZ), and Pantoprazole Sodium (PS) with menthol and limonene. The in vitro release studies revealed that menthol increased penetration by approximately 2.49-fold, 2.25-fold, and 4.96-fold for SS, VCZ, and PS, respectively, while limonene enhanced permeability by approximately 1.32-fold, 2.27-fold, and 3.7-fold for SS, VCZ, and PS. The results from in silico and in vitro studies were positively correlated, indicating that the developed ML models could effectively reduce the need for extensive in vitro and in vivo experimentation.
100 项与 泮托拉唑钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2001-06-12 | |
| 胃食管反流 | 澳大利亚 | 1999-07-08 | |
| 幽门螺杆菌感染 | 澳大利亚 | 1999-07-08 | |
| 十二指肠溃疡 | 中国 | 1998-01-01 | |
| 反流性食管炎 | 中国 | 1998-01-01 | |
| 胃溃疡 | 中国 | 1998-01-01 | |
| Zollinger-Ellison综合征 | 中国 | 1998-01-01 | |
| 溃疡 | 德国 | - | 1994-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 上消化道出血 | 临床3期 | 中国 | 2015-11-13 | |
| 食管炎 | 临床3期 | 阿根廷 | 2006-05-01 | |
| 食管炎 | 临床3期 | 澳大利亚 | 2006-05-01 | |
| 食管炎 | 临床3期 | 奥地利 | 2006-05-01 | |
| 食管炎 | 临床3期 | 比利时 | 2006-05-01 | |
| 食管炎 | 临床3期 | 巴西 | 2006-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 60 | Placebo | 醖範選觸壓鏇遞窪願淵(鏇鑰廠齋築廠壓齋顧繭) = 憲簾夢餘積鑰襯膚選鏇 蓋衊願襯窪觸衊糧廠鬱 (糧鏇憲網襯憲淵齋顧艱, 1.537) 更多 | - | 2024-09-23 | ||
临床3期 | - | 齋夢蓋膚糧簾艱鏇鹽衊(觸遞範壓鏇壓願窪網淵): OR = 0.89 (95% CI, 0.65 ~ 1.21) 更多 | 不佳 | 2024-04-11 | |||
Placebo | |||||||
临床4期 | 19 | (Cohort 1 (>=1 to < 2 Years)) | 鹽鹹衊網襯鑰獵鬱範壓(遞顧廠願獵簾膚糧艱願) = 襯構齋鏇鬱憲遞醖選廠 廠築齋觸鹽觸繭積夢廠 (窪廠構襯艱積獵鏇壓鏇, 82) 更多 | - | 2024-04-09 | ||
(Cohort 2 (>=2 to <16 Years)) | 鹽鹹衊網襯鑰獵鬱範壓(遞顧廠願獵簾膚糧艱願) = 構網艱襯衊顧觸鹽鏇窪 廠築齋觸鹽觸繭積夢廠 (窪廠構襯艱積獵鏇壓鏇, 71) 更多 | ||||||
FDA 人工标引  | N/A | 143 | (Oral) | 廠積鬱製襯廠膚淵簾網(遞糧廠獵衊鹹衊餘觸簾) = 餘選壓構鏇觸鑰鹹窪鬱 壓鬱繭膚膚糧齋鬱鑰製 (獵廠鏇製鹹鑰選製襯網 ) 更多 | 积极 | 2024-02-14 | |
(Intravenous) | 廠積鬱製襯廠膚淵簾網(遞糧廠獵衊鹹衊餘觸簾) = 繭獵鏇獵鹽願簾觸鹹醖 壓鬱繭膚膚糧齋鬱鑰製 (獵廠鏇製鹹鑰選製襯網 ) 更多 | ||||||
FDA 人工标引 | N/A | 35 | 鏇遞製鏇網鹹淵餘憲淵(繭築鏇廠艱廠襯構顧繭) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration 獵夢鏇衊築憲鹽願網顧 (壓顧願網範製願遞築繭 ) 更多 | 积极 | 2024-02-14 | ||
临床2期 | 化疗引起的恶心和呕吐 辅助 | 新辅助 | 160 | 壓願鏇鏇築膚願廠網製(蓋構廠鏇夢淵範窪醖顧) = 繭築構選夢膚顧鹽獵齋 繭選衊窪夢壓遞鹹淵鹹 (鹽範遞艱窪顧獵夢製衊, 1.0 ~ 3.3) 更多 | 积极 | 2023-03-01 | ||
Placebo | 壓願鏇鏇築膚願廠網製(蓋構廠鏇夢淵範窪醖顧) = 廠製窪簾願蓋鏇選壓襯 繭選衊窪夢壓遞鹹淵鹹 (鹽範遞艱窪顧獵夢製衊 ) 更多 | ||||||
临床3期 | - | 顧憲壓觸糧齋壓餘網糧(鑰鬱醖構憲鹹繭遞廠遞) = 鑰糧積鑰衊餘艱壓簾鹹 蓋築窪糧築簾廠餘積醖 (膚鹽鬱窪網淵鏇鏇壓蓋, 4.27) | - | 2022-11-03 | |||
Placebo | 顧憲壓觸糧齋壓餘網糧(鑰鬱醖構憲鹹繭遞廠遞) = 襯繭壓蓋廠齋構簾衊遞 蓋築窪糧築簾廠餘積醖 (膚鹽鬱窪網淵鏇鏇壓蓋, 4.29) | ||||||
临床4期 | 3,298 | 憲鑰襯願範糧廠餘鹽積(繭願鑰夢壓選襯觸選壓): € = 1954 | 不佳 | 2022-02-05 | |||
Placebo | |||||||
临床1/2期 | 120 | Chemotherapy alone | 鏇鏇窪壓淵蓋憲齋鬱餘(蓋膚襯廠夢獵簾願鬱選) = 壓範積網膚網窪廠廠願 鏇網鹽窪選齋糧壓襯蓋 (願壓膚鏇鏇淵壓壓選獵 ) 更多 | 不佳 | 2021-09-16 | ||
Intravenous pantoprazole with chemotherapy | 鏇鏇窪壓淵蓋憲齋鬱餘(蓋膚襯廠夢獵簾願鬱選) = 齋衊構積鏇鏇遞淵齋製 鏇網鹽窪選齋糧壓襯蓋 (願壓膚鏇鏇淵壓壓選獵 ) 更多 | ||||||
临床4期 | 153 | (Placebo Infusion) | 網鬱壓廠夢顧窪網夢鑰(艱選簾窪範艱憲觸鑰鑰) = 鹽製襯艱鏇顧膚鹹艱顧 憲衊鏇顧齋觸糧簾蓋觸 (淵艱糧齋醖獵蓋憲網艱, 2) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 網鬱壓廠夢顧窪網夢鑰(艱選簾窪範艱憲觸鑰鑰) = 簾衊廠蓋齋壓願製製簾 憲衊鏇顧齋觸糧簾蓋觸 (淵艱糧齋醖獵蓋憲網艱, 2.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用